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Objective:Tocompare the long-termriskof primarynon-
melanoma skin cancer (NMSC) and the risk of subse-
quent NMSC in kidney and heart transplant recipients.
Design: Partially retrospective cohort study.
Setting: Two Italian transplantation centers.
Patients: The study included 1934 patients: 1476 renal
transplant recipients and 458 heart transplant recipients.
MainOutcomeMeasures:Cumulative incidences and
risk factors of the first and subsequent NMSCs.
Results: Two hundred patients developed a first NMSC
after a median follow-up of 6.8 years after transplanta-
tion. The 3-year risk of the primary NMSC was 2.1%. Of
the 200 patients with a primary NMSC, 91 (45.5%) had a
secondNMSCafter amedian follow-upafter the firstNMSC
of 1.4 years (range, 3months to 10 years). The 3-year risk
of a second NMSCwas 32.2%, and it was 49 times higher
than that in patients with no previous NMSC. In a Cox
proportional hazards regressionmodel, age older than 50
years at the time of transplantation andmale sexwere sig-
nificantly related to the firstNMSC.Occurrence of the sub-
sequent NMSC was not related to any risk factor consid-
ered, including sex, age at transplantation, type of
transplanted organ, type of immunosuppressive therapy,
histologic type of the first NMSC, and time since diagno-
sis of the first NMSC. Histologic type of the first NMSC
strongly predicted the type of the subsequent NMSC.
Conclusions: Development of a first NMSC confers a
high risk of a subsequent NMSC in transplant recipi-
ents. Intensive long-termdermatologic follow-up of these
patients is advisable.
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P ATIENTS UNDERGOING SOLIDorgan transplantation are atincreased risk for nonmela-noma skin cancers (NMSCs),mostly squamous cell carci-
noma (SCC) and basal cell carcinoma
(BCC), and various risk factors have been
well documented.1-3 Incidence rates of post-
transplantation NMSC differ according to
geographic latitudes; in Italy, they are ap-
proximately 5% after 5 years and 10% after
10 years.4 Higher rates have been observed
in northernEurope (10%after 10 years and
40% after 20 years) and in Australia (45%
after 11years and70%after 20years).5,6 The
reported average time to the development
of NMSC is estimated to range from 4 to 9
years afterorgan transplantation.1-7Male sex,
older age at transplantation, and longer fol-
low-up after transplantationwere indepen-
dently associatedwith the onset ofNMSC.4
Otherpredictors ofNMSCafter organ trans-
plantation are skin phototypes I to III ac-
cording to the Fitzpatrick scale, an exces-
sive sun exposure history, aggressive
immunosuppressive protocols, cumula-
tive dosages of immunosuppressive drugs,
and genetic factors.5,8-13 All of these studies
investigatedonly the firstNMSCafter trans-
plantation, but the risk of a subsequent
NMSC after the diagnosis of a first NMSC
iswell recognized in daily clinical practice.
A comprehensive meta-analysis14 in
nonimmunosuppressed patients re-
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ported a 3-year cumulative risk of 35% to 60% of a sub-
sequent NMSC after a first NMSC of any type, BCC or
SCC, with at least a 10-fold increase in incidence com-
pared with the incidence of first tumors in the general
population. In most patients, the histologic type of the
subsequent NMSC was the same as that of the first
NMSC.14 In a recent study,15 patients with both BCC and
SCC were found to be at decreased risk of subsequent
BCC compared with patients with BCC only. Male sex,
older age, excessive recreational sun exposure, and the
number of tumors at first consultation were considered
independent predictors of the subsequent NMSC.14,15 In
solid organ transplant recipients, Euvrard et al16 re-
ported a 5-year cumulative risk of 71% of developing a
second NMSC after a first index SCC. In this study, in-
dependent predictors of subsequent NMSC were mul-
tiple skin cancers at first examination, blue eyes, fair skin,
blond hair, and transplantation before 1984. Minimiza-
tion of immunosuppressive therapy after diagnosis of the
first NMSC seemed to be protective.16 To our knowl-
edge, no studies have compared the risk factors of the
first and subsequent NMSCs in transplant recipients. Bet-
ter understanding of the timing of and the risk factors
for a subsequent NMSC in solid organ transplant recipi-
ents would help in the design of a more rational fol-
low-up approach to these patients.17 The aim of this study
was to analyze the incidence rates of, the timing of, and
the risk factors for a second NMSC occurring after a first
NMSC in a cohort of Italian kidney and heart transplant
recipients.
METHODS
This was a partially retrospective cohort study. Between Janu-
ary 1, 1993, and December 31, 2008, 1934 consecutive kidney
and heart transplant recipients at 2 Italian transplantation
centers (Verona and Bergamo) were regularly followed up
after transplantation. All of the patients were seen regularly at
the outpatient nephrologic or cardiosurgical clinic, and those
with cutaneous lesions were also seen by a dermatologist. In
addition, every effort was made to collect information on any
dermatologic diagnoses made outside the study centers.
Detailed clinical records were available for all participants.
Patients who had received the graft before the beginning of
the study (367 of 1934 patients [19.0%]) were interviewed if
they had undergone surgery for NMSC, and an accurate
review was performed of their medical history, of the trans-
plant registry, and of all the available clinical records. The
diagnosis of NMSC was always confirmed by histologic analy-
sis. Only patients with BCC and SCC were included in the
present study. Thirteen patients, 9 with Bowen disease and 4
with keratoacanthoma, were excluded. For each patient, the
following data were collected: age, sex, date of transplanta-
tion, type of immunosuppressive therapy, date of the first and
second NMSCs (if any), and date and cause of loss from
follow-up. For patients with NMSC, skin type, eye and hair
color, and the presence of cutaneous keratotic lesions were
also recorded. The NMSC had to meet 2 criteria to be consid-
ered new: the site of the new cancer could not be contiguous
to a scar, which could represent a previously treated NMSC
site, and it had to occur at least 3 months after treatment of
the first NMSC. Patients with recurring NMSC at the site of a
previous surgical procedure were not included in the present
study. Seven patients developed the second NMSC within 3
months of the first NMSC and were excluded. Informed con-
sent was provided by all the participants, and the study was
approved by the local ethics committee.
IMMUNOSUPPRESSIVE THERAPY
Induction therapy andmaintenance immunosuppressive therapy
varied bymedical center and transplanted organ. Inductionwas
usually performed with anti–interleukin 2 receptor monoclo-
nal antibody (Simulect; Novartis AG, Basel, Switzerland) or an-
tithymocyte immunoglobulins (bioMe´rieux Italia s.p.a., Bagno
a Ripoli, Italy or Genzyme Corp, Cambridge, Massachusetts).
Long-term maintenance immunosuppressive therapy, either
alone or in various combinations, included azathioprine (1.0-
2.5 mg/kg/d), cyclosporine (3-9 mg/kg/d), oral methylpred-
nisolone (5-10mg/d), oral tacrolimus (0.15-0.30mg/kg/d), my-
cophenolate mofetil (2 g/d), and, with increasing frequency,
sirolimus or everolimus.11-13 Acute rejectionwas usually treated
with pulsed methylprednisolone (0.5-1.0 g/d for 3 consecu-
tive days). Corticosteroid-resistant acute rejection was treated
with plasmapheresis, muromonab (anti-CD3 monoclonal an-
tibody), or antithymocyte immunoglobulins.14-16,18,19
STATISTICAL ANALYSIS
Cumulative incidences of the first and secondNMSCswere com-
puted. Concerning the first NMSC, the number of person-years
was computed between the date of transplantation (used as the
opening date) and the date of NMSCdiagnosis (considered to be
the end point), the patient’s death, loss to follow-up, or the end
of the study (December 31, 2008) (used as closing dates).When
evaluating the second NMSC, the number of person-years was
computed between the date of the first NMSC diagnosis and the
date of the second NMSC diagnosis (considered to be the end
point), thepatient’s death, loss to follow-up, or the endof the study
(December 31, 2008). Kaplan-Meier survival curves were ini-
tially constructed. Subsequently, for estimates of potential prog-
nostic factors, a Cox proportional hazards regressionmodel was
applied. An assumption of the Cox regressionmethod is that the
hazards for different strata of each independent variable are pro-
portional over time. This assumptionwas verified using a graphi-
cal method. The survival curves for the variable strata were plot-
ted on a log-log scale. If the curves were approximately parallel,
then the assumption of the proportional hazards was considered
satisfied. Abackward stepping procedurewith preassignedP=.05
for removal of variables was used.20 Statistical analyses were per-
formedusinga statistical softwarepackage (Stata, version10; Stata-
Corp LP, College Station, Texas).
RESULTS
The characteristics of the study population are reported
in Table 1. There were 1344men and 590women; 1476
patientswere renal transplant recipients and458wereheart
transplant recipients; themean (SD) follow-up time since
transplantation was 9.2 (6.6) years (median, 8.0 years;
range, 1.0-33.0 years). Two hundred patients (146 renal
transplant recipients and 54 heart transplant recipients)
developed a first NMSC after a mean (SD) follow-up of
8.4 (6.1) years and amedian follow-up of 6.8 years (range,
1.5-15.2 years). No differences existed between renal and
heart transplant recipients. Eleven of 200 patients
(5.5%)—9 renal transplant recipients and 2 heart trans-
plant recipients—had 2 ormoreNMSCs at the time of the
diagnosis of the first NMSC. Two renal transplant recipi-
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ents died of metastatic SCC. The cumulative incidence of
the first NMSC since transplantation increased progres-
sively from 0.4% after 1 year to 21.3% after 20 years
(Figure 1A). The 3-year risk of the primary NMSC was
2.1%.Of the200patientswith aprimaryNMSC,91 (45.5%)
had a secondNMSC after amean (SD) follow-up since the
first NMSC of 2.2 (2.1) years and a median follow-up of
1.4 years (range, 3 months to 10 years). The cumulative
incidence of the secondNMSCwasmuch higher and also
increased over time from 14.4% after 1 year to 61.5% af-
ter 10 years (Figure 1B). The 3-year risk of a secondNMSC
was 32.2%. Patients with a first NMSC had a probability
of developing a second NMSC after 1, 3, 5, and 10 years
of 33, 49, 10, and 6 times higher than that in patients with
no previous NMSC. Table 2 describes the clinical char-
acteristics of patients with a first NMSC and of those with
a second NMSC. The head and neck were the most com-
monly affected sites. Most patients with NMSC belonged
to phototypes III and IV according to the Fitzpatrick scale.
When statistical analyses were stratified according to the
transplanted organ, no substantial differences were ob-
served. Table 3 shows the risk factors for the onset of
the first and secondNMSCs calculated using theCox pro-
portional hazards regressionmodel. Older age at the time
of transplantation and male sex were independently re-
lated to the first NMSC. The second NMSC was not re-
lated to sex, age at transplantation, type of transplanted
organ, type of immunosuppressive therapy, length of fol-
low-up at the diagnosis of the first NMSC, and type of the
first NMSC. In a further analysis that considered the sub-
sequent BCC and SCC as separate end points, the histo-
logic type of the first NMSC strongly predicted the risk of
a subsequent NMSC of the same type (Table 3 and
Figure 2). Further analysis taking into account the skin
site of the first cancer (photo exposed vs non–photo ex-
posed), phototype, eye and hair color, and the presence
of actinic keratoses at diagnosis of the first NMSC gave no
statistically significant results (data not shown). Types and
dosages of immunosuppressive drugs were not changed
after diagnosis of the first NMSC.
Table 1. Characteristics of the Study Population
Characteristic
Renal Transplant Recipients
(n=1476)
Heart Transplant Recipients
(n=458)
Sex, No. M/F 974/502 370/88
Age at transplantation, y
Mean (SD) 44.4 (16.7) 50.1 (15.1)
Median (range) 43.8 (20.1-60.8) 53.4 (26.3-65.9)
Posttransplantation person-years, No. 14 675 4214
Follow-up after transplantation, y
Mean (SD) 9.4 (7.0) 8.7 (4.8)
Median (range) 8 (1.0-33.0) 9 (1.0-20.0)
Immunosuppressive therapy, No. (%)
1 Drugprednisolone 664 (45.0) 279 (60.9)
2 Drugsprednisolone 812 (55.0) 179 (39.1)
Censored observations, No.
Lost to follow-up 75 5
Death 133 49
Chronic rejection of the graft 118 45
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Figure 1. Cumulative incidences of the first (A) and second (B) nonmelanoma skin cancers (NMSCs) in the study population. Vertical bars indicate 95%
confidence intervals.
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Table 2. Clinical Characteristics of Transplant Recipients With a First NMSC and With a Second NMSC
Characteristic Patients With a First NMSC (n=200) Patients With a Second NMSC (n=91)
Follow-up at diagnosis of NMSC, y
Mean (SD) 8.4 (6.1)a 2.2 (2.1)b
Median (range) 6.8 (1.5-15.2) 1.4 (0.2-10)
Type of transplanted organ, No. (%)
Kidney 146 (73.0) 71 (78.0)
Heart 54 (27.0) 20 (22.0)
Type of NMSC, No. (%)
SCC 109 (54.5) 50 (54.9)
BCC 91 (45.5) 41 (45.1)
Site of NMSC, No. (%)
Head and neck 117 (58.5) 50 (54.9)
Trunk 44 (22.0) 16 (17.6)
Upper arms 34 (17.0) 14 (15.4)
Lower legs 5 (2.5) 11 (12.1)
Immunosuppressive therapy, No. (%)
1 Drugprednisolone 105 (52.5) 35 (38.5)
2 Drugsprednisolone 95 (47.5) 56 (61.5)
Eye color, No. (%)
Black or brown 108 (54.0) 47 (51.6)
Blue or green 92 (46.0) 44 (48.4)
Hair color, No. (%)
Black or brown 151 (75.5) 65 (71.4)
Blond or red 49 (24.5) 26 (28.6)
Skin type according to the Fitzpatrick scale, No. (%)c
I 11 (5.5) 5 (5.5)
II 29 (14.5) 15 (16.5)
III 100 (50.0) 43 (47.3)
IV 60 (30.0) 28 (30.8)
Presence of actinic keratoses, No. (%)
0-5 132 (66.0) 53 (58.2)
5 68 (34.0) 38 (41.8)
Abbreviations: BCC, basal cell carcinoma; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma.
aFollow-up at diagnosis of the first NMSC was measured from transplantation.
bFollow-up at diagnosis of the second NMSC was measured from the date of the first NMSC.
cPhototype I (scores 0-7): white, very fair; red or blond hair; blue eyes; freckles; always burns, never tans. Phototype II (scores 8-16): white, fair; red or blond
hair; blue, hazel, or green eyes; usually burns, tans with difficulty. Phototype III (scores 17-25): cream white, fair; any eye or hair color; very common; sometimes
mild burn, gradually tans. Phototype IV (scores 25-30): dark brown; typical Mediterranean Caucasian skin; rarely burns, tans with ease.
Table 3. Risk Factors for Onset of the First NMSC in the Whole Study Cohort of 1934 Patients and of the Second NMSC
in 200 Patients With a First NMSC
Risk Factor
Patients,
No.
First NMSC
Patients,
No.
Subsequent NMSC Subsequent BCC Subsequent SCC
Hazard Ratioa
(95% CI)
P
Value
Hazard Ratioa
(95% CI)
P
Value
Hazard Ratioa
(95% CI)
P
Value
Hazard Ratioa
(95% CI)
P
Value
Sex
Female 590 1 [Reference] 40 1 [Reference] 1 [Reference] 1 [Reference]
Male 1344 1.6 (1.2-2.3) .007 160 1.2 (0.6-2.0) .60 1.3 (0.5-3.1) .54 1.6 (0.6-4.1) .27
Type of transplanted organ
Heart 458 1 [Reference] 54 1 [Reference] 1 [Reference] 1 [Reference]
Kidney 1476 0.8 (0.6-1.2) .49 146 0.9 (0.5-1.5) .71 0.6 (0.2-1.5) .32 0.7 (0.2-1.6) .42
Age at transplantation, y
30 370 1 [Reference] 22 1 [Reference] 1 [Reference] 1 [Reference]
30-50 821 2.2 (1.3-3.5) .002 84 1.2 (0.5-2.3) .74 1.2 (0.3-4.4) .73 0.7 (0.2-2.5) .67
50 743 5.4 (3.2-9.0) .001 94 1.1 (0.5-2.7) .68 1.0 (0.2-4.3) .92 1.2 (0.3-5.0) .76
Immunosuppressive therapy
1 Drugprednisolone 951 1 [Reference] 99 1 [Reference] 1 [Reference] 1 [Reference]
2 Drugsprednisolone 983 1.3 (0.9-1.7) .13 101 0.6 (0.3-1.0) .09 0.4 (0.2-1.0) .054 0.7 (0.3-1.4) .42
Years from transplantation
to diagnosis of the
first NMSCb
NA NA NA NA 0.9 (0.9-1.0) .89 0.9 (0.9-1.0) .41 1.0 (0.9-1.0) .36
Type of the first NMSC
SCC NA NA NA 109 1 [Reference] 1 [Reference] 1 [Reference]
BCC NA NA NA 91 0.8 (0.5-1.3) .61 3.8 (1.6-8.9) .002 0.2 (0.1-0.4) .001
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; NA, not applicable; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma.
aMultivariate estimates were derived using a Cox proportional hazards regression model.
bThe length of follow-up from transplantation to diagnosis of the first NMSC was inserted in the model as a continuous variable.
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COMMENT
The main finding of the present study was that trans-
plant recipientswith a first NMSChave an increased long-
term probability of developing a subsequent NMSC
compared with patients with no previous NMSC, thus
confirming the findings of Euvrard et al.16 In the present
cohort, the 5-year risk of subsequent NMSC was 41.8%,
which is significantly lower than that in the study by
Euvrard et al,16 a difference possibly related to the lower
incidence of NMSC in the present study population com-
pared with other studies conducted in northern Europe,
Australia, and Canada.1-8
None of the clinical risk factors for the first NMSC
could predict the onset of the second NMSC, possibly
because the risk factors for the first NMSC remain in the
patients who develop another. The number of patients
with actinic keratoses was higher in patients with and
without a subsequent cancer. Only a few of these pa-
tients had other risk factors, such as fair skin, blond hair,
blue eyes, or multiple skin cancers at the first consulta-
tion. Most patients with NMSC belonged to phototypes
III and IV, themost common phototypes observed in the
nonimmunosuppressed Italian population. Time since
transplantation at diagnosis of the first cancer could not
predict onset of the subsequent NMSC, supporting the
need for regular long-term dermatologic surveillance of
all the transplant recipients.
A possible bias in this study was the lack of data about
sun exposure (forwork and leisure) before and after trans-
plantation and the adoption of sun-protective measures
after diagnosis of the first NMSC; however, patients are
often not reliable when reporting this information.
The impact of a specific type of immunosuppressive
therapy on the onset of skin cancer has been extensively
investigated but is still unclear.2,12,13 In a previous study4
and in the present data, the risk of NMSC was not re-
lated to a specific immunosuppressive regimen. Study-
ing the effect of a single drug protocol may be difficult
because the type and amount of immunosuppressive drugs
can change during follow-up. Reductions of immuno-
suppressive therapy, administration of oral retinoids, and
conversion to sirolimus-based immunosuppressive
therapy have been proposed to reduce the risk of subse-
quent NMSC in transplant recipients.21-23 However, at the
time of this writing, these protocols were not in use in
the transplantation centers of Verona and Bergamo.
In the present cohort, the histologic type of the first
NMSC strongly predicted the risk of having a subse-
quent NMSC of the same type, thus confirming data ob-
served in nonimmunosuppressed patients.14 This find-
ing may affect the clinical management of patients,
especially those with SCC, which may be aggressive and
metastatic, as observed in 2 of the present patients. In
conclusion, these data demonstrate that solid organ trans-
plant recipients with a first NMSC are at high risk for a
second NMSC. No clinical predictors are currently rec-
ognized. Intensive lifelong dermatologic follow-up is ad-
visable for these patients.
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Figure 2. Cumulative incidences of the second basal cell carcinoma (BCC) (A) and of the second squamous cell carcinoma (SCC) (B) in the study population,
stratified according to the type of the first nonmelanoma skin cancer (NMSC). Vertical bars indicate 95% confidence intervals.
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